Ads
related to: burkitt's lymphoma survival rate
Search results
Results from the WOW.Com Content Network
Burkitt's lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal center.It is named after Denis Parsons Burkitt, the Irish surgeon who first described the disease in 1958 while working in equatorial Africa.
Burkitt lymphoma/leukemia < 1% of lymphomas in the United States Round lymphoid cells of intermediate size with several nucleoli, starry-sky appearance by diffuse spread with interspersed apoptosis CD10, surface Ig Five-year survival rate 50% [37]
Burkitt lymphoma occurs in three forms. Epidemic Burkitt lymphoma (eBL) is common in Africa, the Middle East, Brazil, Papua New Guinea, and other areas where malaria is endemic. It usually presents in children 4–7 years old and in almost all cases is associated with EBV infection. [31] Sporadic Burkitt lymphoma (sBL) is rare.
CD20. Approximately 95% of B-cell lymphomas express CD20, but CD20 is not critical for B-cell survival. Clonal B-cells spontaneously mutate the idiotypic region of their immunoglobulin. This high mutation rate makes them prone to the selection of B-cells lacking the CD20 antigen following treatment with CD20-targeting monoclonal antibodies.
While DLBCL-CI, particularly in its PAL form, is an aggressive lymphoma with a five-year overall survival rate of 20–35%, FA-DLBCL, usually has a highly favorable outcome except when it involves the heart (e.g. in myxomas or on prosthetic valves) or vasculature structures (e.g. on thrombus-laden vascular grafts), in which cases life ...
In Burkitt's lymphoma and mantle cell lymphoma, the other protein in the fusion is c-myc (on chromosome 8) and cyclin D1 [9] (on chromosome 11), respectively, which gives the fusion protein pro-proliferative ability.
Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies.It is the most common form of non-Hodgkin lymphoma among adults, [1] with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK.
Median survival is 10 to 18 months in immunocompetent patients, and less in those with AIDS. The addition of IV methotrexate and folinic acid (leucovorin) may extend survival to a median of 3.5 years. If radiation is added to methotrexate, median survival time may increase beyond 4 years.
Ads
related to: burkitt's lymphoma survival rate